Deciphering cellular biological processes to clinical application: a new perspective for Tα1 treatment targeting multiple diseases

Claudia Matteucci, Ayele Argaw-Denboba, Emanuela Balestrieri, Alessandro Giovinazzo, Martino Miele, Cartesio D’Agostini, Francesca Pica, Sandro Grelli, Maurizio Paci, Antonio Mastino, Paola Sinibaldi Vallebona, Enrico Garaci, Carlo Tomino

Research output: Contribution to journalArticle

Abstract

Background: Thymosin alpha 1 (Tα1) is a well-recognized immune response modulator in a wide range of disorders, particularly infections and cancer. The bioinformatic analysis of public databases allows drug repositioning, predicting a new potential area of clinical intervention. We aimed to decipher the cellular network induced by Tα1 treatment to confirm present use and identify new potential clinical applications. Research design and methods: We used the transcriptional profile of human peripheral blood mononuclear cells treated in vitro with Tα1 to perform the enrichment network analysis by the Metascape online tools and the disease enrichment analysis by the DAVID online tool. Results: Networked cellular responses reflected Tα1 regulated biological processes including immune and metabolic responses, response to compounds and oxidative stress, ion homeostasis, peroxisome biogenesis and drug metabolic process. Beyond cancer and infections, the analysis evidenced the association with disorders such as kidney chronic failure, diabetes, cardiovascular, chronic respiratory, neuropsychiatric, neurodegenerative and autoimmune diseases. Conclusions: In addition to the known ability to promote immune response pathways, the network enrichment analysis demonstrated that Tα1 regulates cellular metabolic processes and oxidative stress response. Notable, the analysis highlighted the association with several diseases, suggesting new translational implication of Tα1 treatment in pathological conditions unexpected until now.

Original languageEnglish
Pages (from-to)23-31
Number of pages9
JournalExpert Opinion on Biological Therapy
Volume18
Issue numberSup 1
DOIs
Publication statusPublished - May 31 2018

Fingerprint

Biological Phenomena
Oxidative stress
Oxidative Stress
Drug Repositioning
Association reactions
Peroxisomes
Bioinformatics
Medical problems
Electric network analysis
Infection
Computational Biology
Neurodegenerative Diseases
Pharmaceutical Preparations
Modulators
Autoimmune Diseases
Chronic Kidney Failure
thymalfasin
Blood Cells
Neoplasms
Homeostasis

Keywords

  • Cancer
  • chronic disease
  • drug repositioning
  • drug target discovery
  • enrichment analysis
  • infectious diseases
  • thymosin alpha

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Deciphering cellular biological processes to clinical application : a new perspective for Tα1 treatment targeting multiple diseases. / Matteucci, Claudia; Argaw-Denboba, Ayele; Balestrieri, Emanuela; Giovinazzo, Alessandro; Miele, Martino; D’Agostini, Cartesio; Pica, Francesca; Grelli, Sandro; Paci, Maurizio; Mastino, Antonio; Sinibaldi Vallebona, Paola; Garaci, Enrico; Tomino, Carlo.

In: Expert Opinion on Biological Therapy, Vol. 18, No. Sup 1, 31.05.2018, p. 23-31.

Research output: Contribution to journalArticle

Matteucci, C, Argaw-Denboba, A, Balestrieri, E, Giovinazzo, A, Miele, M, D’Agostini, C, Pica, F, Grelli, S, Paci, M, Mastino, A, Sinibaldi Vallebona, P, Garaci, E & Tomino, C 2018, 'Deciphering cellular biological processes to clinical application: a new perspective for Tα1 treatment targeting multiple diseases', Expert Opinion on Biological Therapy, vol. 18, no. Sup 1, pp. 23-31. https://doi.org/10.1080/14712598.2018.1474198
Matteucci, Claudia ; Argaw-Denboba, Ayele ; Balestrieri, Emanuela ; Giovinazzo, Alessandro ; Miele, Martino ; D’Agostini, Cartesio ; Pica, Francesca ; Grelli, Sandro ; Paci, Maurizio ; Mastino, Antonio ; Sinibaldi Vallebona, Paola ; Garaci, Enrico ; Tomino, Carlo. / Deciphering cellular biological processes to clinical application : a new perspective for Tα1 treatment targeting multiple diseases. In: Expert Opinion on Biological Therapy. 2018 ; Vol. 18, No. Sup 1. pp. 23-31.
@article{cca1c856bc3c4c3abffd90a57b0a1267,
title = "Deciphering cellular biological processes to clinical application: a new perspective for Tα1 treatment targeting multiple diseases",
abstract = "Background: Thymosin alpha 1 (Tα1) is a well-recognized immune response modulator in a wide range of disorders, particularly infections and cancer. The bioinformatic analysis of public databases allows drug repositioning, predicting a new potential area of clinical intervention. We aimed to decipher the cellular network induced by Tα1 treatment to confirm present use and identify new potential clinical applications. Research design and methods: We used the transcriptional profile of human peripheral blood mononuclear cells treated in vitro with Tα1 to perform the enrichment network analysis by the Metascape online tools and the disease enrichment analysis by the DAVID online tool. Results: Networked cellular responses reflected Tα1 regulated biological processes including immune and metabolic responses, response to compounds and oxidative stress, ion homeostasis, peroxisome biogenesis and drug metabolic process. Beyond cancer and infections, the analysis evidenced the association with disorders such as kidney chronic failure, diabetes, cardiovascular, chronic respiratory, neuropsychiatric, neurodegenerative and autoimmune diseases. Conclusions: In addition to the known ability to promote immune response pathways, the network enrichment analysis demonstrated that Tα1 regulates cellular metabolic processes and oxidative stress response. Notable, the analysis highlighted the association with several diseases, suggesting new translational implication of Tα1 treatment in pathological conditions unexpected until now.",
keywords = "Cancer, chronic disease, drug repositioning, drug target discovery, enrichment analysis, infectious diseases, thymosin alpha",
author = "Claudia Matteucci and Ayele Argaw-Denboba and Emanuela Balestrieri and Alessandro Giovinazzo and Martino Miele and Cartesio D’Agostini and Francesca Pica and Sandro Grelli and Maurizio Paci and Antonio Mastino and {Sinibaldi Vallebona}, Paola and Enrico Garaci and Carlo Tomino",
year = "2018",
month = "5",
day = "31",
doi = "10.1080/14712598.2018.1474198",
language = "English",
volume = "18",
pages = "23--31",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "Sup 1",

}

TY - JOUR

T1 - Deciphering cellular biological processes to clinical application

T2 - a new perspective for Tα1 treatment targeting multiple diseases

AU - Matteucci, Claudia

AU - Argaw-Denboba, Ayele

AU - Balestrieri, Emanuela

AU - Giovinazzo, Alessandro

AU - Miele, Martino

AU - D’Agostini, Cartesio

AU - Pica, Francesca

AU - Grelli, Sandro

AU - Paci, Maurizio

AU - Mastino, Antonio

AU - Sinibaldi Vallebona, Paola

AU - Garaci, Enrico

AU - Tomino, Carlo

PY - 2018/5/31

Y1 - 2018/5/31

N2 - Background: Thymosin alpha 1 (Tα1) is a well-recognized immune response modulator in a wide range of disorders, particularly infections and cancer. The bioinformatic analysis of public databases allows drug repositioning, predicting a new potential area of clinical intervention. We aimed to decipher the cellular network induced by Tα1 treatment to confirm present use and identify new potential clinical applications. Research design and methods: We used the transcriptional profile of human peripheral blood mononuclear cells treated in vitro with Tα1 to perform the enrichment network analysis by the Metascape online tools and the disease enrichment analysis by the DAVID online tool. Results: Networked cellular responses reflected Tα1 regulated biological processes including immune and metabolic responses, response to compounds and oxidative stress, ion homeostasis, peroxisome biogenesis and drug metabolic process. Beyond cancer and infections, the analysis evidenced the association with disorders such as kidney chronic failure, diabetes, cardiovascular, chronic respiratory, neuropsychiatric, neurodegenerative and autoimmune diseases. Conclusions: In addition to the known ability to promote immune response pathways, the network enrichment analysis demonstrated that Tα1 regulates cellular metabolic processes and oxidative stress response. Notable, the analysis highlighted the association with several diseases, suggesting new translational implication of Tα1 treatment in pathological conditions unexpected until now.

AB - Background: Thymosin alpha 1 (Tα1) is a well-recognized immune response modulator in a wide range of disorders, particularly infections and cancer. The bioinformatic analysis of public databases allows drug repositioning, predicting a new potential area of clinical intervention. We aimed to decipher the cellular network induced by Tα1 treatment to confirm present use and identify new potential clinical applications. Research design and methods: We used the transcriptional profile of human peripheral blood mononuclear cells treated in vitro with Tα1 to perform the enrichment network analysis by the Metascape online tools and the disease enrichment analysis by the DAVID online tool. Results: Networked cellular responses reflected Tα1 regulated biological processes including immune and metabolic responses, response to compounds and oxidative stress, ion homeostasis, peroxisome biogenesis and drug metabolic process. Beyond cancer and infections, the analysis evidenced the association with disorders such as kidney chronic failure, diabetes, cardiovascular, chronic respiratory, neuropsychiatric, neurodegenerative and autoimmune diseases. Conclusions: In addition to the known ability to promote immune response pathways, the network enrichment analysis demonstrated that Tα1 regulates cellular metabolic processes and oxidative stress response. Notable, the analysis highlighted the association with several diseases, suggesting new translational implication of Tα1 treatment in pathological conditions unexpected until now.

KW - Cancer

KW - chronic disease

KW - drug repositioning

KW - drug target discovery

KW - enrichment analysis

KW - infectious diseases

KW - thymosin alpha

UR - http://www.scopus.com/inward/record.url?scp=85051080670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051080670&partnerID=8YFLogxK

U2 - 10.1080/14712598.2018.1474198

DO - 10.1080/14712598.2018.1474198

M3 - Article

C2 - 30063863

AN - SCOPUS:85051080670

VL - 18

SP - 23

EP - 31

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - Sup 1

ER -